Who is sponsoring NCT05060861?

NCT05060861 is sponsored by Assiut University.

What drugs are being tested in NCT05060861?

Interventions in NCT05060861: ChAdOx1 nCoV-19 vaccine.

What condition does NCT05060861 study?

NCT05060861 studies ChAdOx1 nCoV-19 Vaccine.

Is NCT05060861 still recruiting?

NCT05060861 is currently status unknown. Last updated 29 September 2021.

Last reviewed 2021-09-29 · How we verify

NCT05060861

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Efficacy of Chadox1 Ncov-19 Vaccine: Rapid Systematic Review and Meta Analysis

Status unknown Last updated 29 September 2021

What this trial tests

trial testing ChAdOx1 nCoV-19 vaccine in ChAdOx1 nCoV-19 Vaccine in 2,000 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
30 August 2021

30 October 2021

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	1 June 2021
Primary completion	30 August 2021
Estimated completion	30 October 2021
Sites	1 location across Egypt

Drugs / interventions tested

ChAdOx1 nCoV-19 vaccine

Conditions studied

ChAdOx1 nCoV-19 Vaccine — all drugs for ChAdOx1 nCoV-19 Vaccine →

Sponsor

Assiut University

Who can join

Adults 18 to 80, any sex, with ChAdOx1 nCoV-19 Vaccine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Since the beginning of COVID-19 pandemic, a safe and effective vaccine against infection and development of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed control of the wide spread of COVID-19 and reduce death rates throughout the world. Many clinical trials investigated the immunogenicity of different proposed vaccine including the first distributed vaccine; the ChAdOx1 nCoV-19 vaccine and there is a need to analyze the results of published clinical trials.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05060861 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 29 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05060861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing